Program Description & Educational Objectives

In this activity, experts in the field of melanoma address the impact of new data and innovative therapies on the management of malignant melanoma, focusing on key strategies for integrating relevant clinical science into daily practice.

Upon completion of this activity, participants should be better able to:

• Apply updated clinical practice recommendations and new data for patients with malignant melanoma, including individuals with resectable or advanced, unresectable disease
• Integrate novel immunotherapeutic options for disease management into existing protocols for patients with metastatic melanoma
• Recognize genetic and molecular biomarkers associated with treatment implications in malignant melanoma
• Demonstrate knowledge of the efficacy and safety of targeted agents in advanced melanoma settings
• Identify patient populations with the potential to benefit from rationally designed combinations of immunotherapy, modern chemotherapy, and targeted agents in the setting of malignant melanoma

Target Audience

This activity has been designed to meet the educational needs of medical oncologists and other clinicians involved in the management of malignant melanoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: July 14, 2011 - July 13, 2012
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, the University of Florida College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Interviewee

Antoni Ribas, MD
Associate Professor of Medicine, Hematology-Oncology
Associate Professor of Surgery, Surgical Oncology
Associate Professor of Molecular and Medical Pharmacology
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center (JCCC)
David Geffen School of Medicine
University of California Los Angeles (UCLA)
Los Angeles, California

Antoni Ribas, MD, has a financial interest/relationship or affiliation in the form of:
Honoraria from Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.

Interviewees

John M. Kirkwood, MD
Usher Professor of Medicine, Dermatology, and Translational Science
University of Pittsburgh School of Medicine
Director, Melanoma and Skin Cancer Program
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

John M. Kirkwood, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for GlaxoSmithKline and Morphotek Inc.

Jedd D. Wolchok, MD, PhD
Director, Immunotherapy Clinical Trials
Associate Attending Physician, Melanoma-Sarcoma Service
Associate Director, Medical Oncology-Hematology Fellowship Program
Memorial Sloan-Kettering Cancer Center
New York, New York

Jedd D. Wolchok, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board for Bristol-Myers Squibb.

CME Reviewer

Thomas J. George, MD, FACP
Division of Hematology/Oncology
Assistant Professor
Director, Gastrointestinal Oncology Program
Associate Director, Fellowship Training Program
University of Florida
Gainesville, Florida

Thomas J. George, MD, FACP, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca currently has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Florida College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is jointly sponsored by the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by educational grants from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.